GQG Partners’s Pfizer PFE Stock Holding History

GQG Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.17M	Buy	131,567 +35,075	+36%	+$918K	0.01%	87
2026 Q1	$2.71M	Buy	96,492 +10	+0%	+$266	﹤0.01%	65
2025 Q4	$2.4M	Sell	96,482 -1,174	-1%	-$29.6K	﹤0.01%	67
2025 Q3	$2.49M	Buy	+97,656	New	+$2.41M	﹤0.01%	71
2020 Q1	–	Sell	-9,538	Closed	-$355K	–	70
2019 Q4	$355K	Buy	+9,538	New	+$340K	﹤0.01%	50

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GQG Partners's PFE Position: Q2 2026 in Review

GQG Partners increased its Pfizer (PFE) stake by 36% in Q2 2026, buying an estimated $918K and bringing the position to 131,567 shares worth $3.17M. The position accounts for 0.01% of the portfolio, ranked #87.

GQG Partners first reported a position in PFE in Q4 2019 and has held it in 5 quarters since. 2,429 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

GQG Partners held 131,567 shares of Pfizer worth $3.17M as of Q2 2026.
GQG Partners bought 35,075 Pfizer shares in Q2 2026, an estimated $918K.
Pfizer made up 0.01% of GQG Partners's portfolio in Q2 2026, its #87 holding.
GQG Partners first reported a position in Pfizer in Q4 2019 and has held it in 5 quarters since.
2,429 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on GQG Partners's 13F filing for Q2 2026, filed 12 Aug 2026.